- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04255719
Unilateral GPi vs Unilateral STN DBS in the Same Patient With PD
Unilateral Pallidal vs Unilateral Subthalamic Nucleus Deep Brain Stimulation in the Same Patient With Parkinson Disease: A Randomized Controlled Trial
The subthalamic nucleus (STN) and globus pallidus interna (GPi) are two main targets in the deep brain stimulation (DBS) treatment for Parkinson's disease (PD). Large randomized controlled trials, in which patients of comparable clinical and demographics were randomized to either GPi DBS or STN DBS, have demonstrated equal effects of both targets in motor symptom improvement, the superiority of STN DBS in the medication reduction and the potential advantage of GPi DBS for cognitive, psychiatric and axial aspects. Unfortunately, in such a highly heterogeneous disease of PD, many of these randomized controlled trials didn't include sufficient subjects and thereby yielded inconsistent results. Moreover, most studies are investigating the difference between GPi and STN in different patients.
In order to address the problem, an intra-patient comparison will be made by investigating the acute turning-on effects of unilateral STN stimulation versus unilateral GPi stimulation on axial symptoms, cognition and also cardinal symptoms within each individual patient who received the treatment of combined unilateral STN and contralateral GPi DBS. Axial symptoms including gait, balance and posture, motor symptoms and cognition are comprehensively assessed under two treatment conditions.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Shanghai
-
Shanghai, Shanghai, Porcelana, 200025
- Functional neurosurgery of Shanghai Jiaotong University affiliated Ruijin Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patients with idiopathic Parkinson's disease
- Aged between 55 and 75 years, both male and female
- Patients who have undergone combined unilateral STN and contralateral GPi DBS for more than 6 months
- A Hoehn-Yahr (H-Y) stage of less than 4 in the off-medication state
- A left-extremity to right-extremity ratio of less than 0.15 on the Unified Parkinson's Disease Rating Scale part Ⅲ (UPDRS-Ⅲ) in the both off-medication and on-medication states
Exclusion Criteria:
- History of serious psychosis
- History of intractable epilepsy (i.e., seizures)
- Diagnosed by the investigators that patients with severe cardiac, liver and kidney diseases, or other serious health conditions
- Dementia (A Mini-Mental State Examination (MMSE) score of < 24), inability to comprehend the experimental protocol or voluntarily provide informed consent
- Lack of cooperation
- Additional reasons for exclusion at the discretion of the clinical investigator
- Poorly controlled depression or anxiety
- Past history of suicidal attempt
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Unilateral DBS of the subthalamic nucleus (STN)
To deliver unilateral STN DBS, bilateral stimulation will be turned off for three hours, and then turn on the unilateral STN DBS.
The STN stimulation will be programmed as previous parameter configuration with optimal therapeutic benefits.
Participants will be asked to complete a comprehensive set of assessments under unilateral STN stimulation in the off-medication state.
45 minutes after taking regular medication, participants need to complete the second set of assessments in the on-medication state.
|
Unilateral DBS for treatment of patients with PD
|
Experimental: Unilateral DBS of the globus pallidus interna (GPi)
To deliver unilateral GPi DBS, bilateral stimulation will be turned off for three hours, and then turn on the unilateral GPi DBS.
The study protocol is identical to the intervention of unilateral STN DBS but it was done on a different day.
|
Unilateral DBS for treatment of patients with PD
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Difference in Timed Up-and-Go (TUG) task scores between treatment conditions in the on- and off- medication states
Periodo de tiempo: 6 months
|
Timed Up-and-Go task is a well-defined objective gait measurement.
The task requires an individual to stand up, walk 5 m, turn, walk back, and sit down.
The time taken to complete the test is strongly correlated with the level of functional mobility.
This test will be videotaped and scored by two blinded neurologists.
|
6 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Differences in total Unified Parkinson's Disease Rating Scale Part Ⅲ (UPDRS Ⅲ) scores between two treatment conditions in the on- and off- medication states
Periodo de tiempo: 6 months
|
Unified Parkinson's Disease Rating Scale Part Ⅲ measures the motor severity of Parkinson's disease.
UPDRS Ⅲ score has a range of 0 (no symptoms) to 132 (severe disease symptoms).
|
6 months
|
Differences in Burg Balance Scale (BBS) scores between two treatment conditions in the on- and off- medication states.
Periodo de tiempo: 6 months
|
Burg Balance Scale measures patients' static and dynamic balance abilities.
BBS score has a range of 0 (severe balance problems) to 56 (no balance problems).
|
6 months
|
Differences in postural angles between two treatment conditions in the on- and off- medication states.
Periodo de tiempo: 6 months
|
The measurement of postural angles is the same as the paper (Yamada et al) published in J Neurol Neurosurg Psychiatry
|
6 months
|
Differences in Water Swallow Test (WST) scores between treatment conditions in the on- and off- medication states.
Periodo de tiempo: 6 months
|
The Water Swallow Test is frequently used in clinical practice as a functional assessment to detect dysphagia, with stage 1 indicating severe dysphagia and stage 6 indicating normal swallowing function.
|
6 months
|
Differences in Swallowing Disturbance Questionnaire (SDQ) scores between treatment conditions in the on- and off- medication states.
Periodo de tiempo: 6 months
|
The Swallowing Disturbance Questionnaire is created as a self-rated dysphagia screening tool in PD, with a range of 0 (normal swallowing function) to 42 (severe dysphagia).
|
6 months
|
Differences in voice parameters between treatment conditions in the on- and off- medication states.
Periodo de tiempo: 6 months
|
Voice recording at a sampling rate of 44.1 kHz using 16-bit quantification will be conducted in a sound-treated room using a microphone and a digital voice recorder with a mouth-to-microphone distance of 15 cm.
The recorded voices will then be used for a composit acoustic analysis.
|
6 months
|
Differences in Voice Handicap Index (VHI) between treatment conditions in the on- and off- medication states.
Periodo de tiempo: 6 months
|
The Voice Handicap Index is a self-administered instrument, comprising 30 items on voice-related dysfunction.
VHI has a range of 0 (normal voice function) to 120 (severe voice dysfunction).
|
6 months
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Publicaciones Generales
- Lizarraga KJ, Luca CC, De Salles A, Gorgulho A, Lang AE, Fasano A. Asymmetric neuromodulation of motor circuits in Parkinson's disease: The role of subthalamic deep brain stimulation. Surg Neurol Int. 2017 Oct 24;8:261. doi: 10.4103/sni.sni_292_17. eCollection 2017.
- Yamada K, Shinojima N, Hamasaki T, Kuratsu J. Subthalamic nucleus stimulation improves Parkinson's disease-associated camptocormia in parallel to its preoperative levodopa responsiveness. J Neurol Neurosurg Psychiatry. 2016 Jul;87(7):703-9. doi: 10.1136/jnnp-2015-310926. Epub 2015 Sep 30.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2020 UPS study
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Enfermedad de Parkinson
-
ProgenaBiomeReclutamientoEnfermedad de Parkinson | Enfermedad de Parkinson con demencia | Síndrome de Parkinson-Demencia | Enfermedad de Parkinson 2 | Enfermedad de Parkinson 3 | Enfermedad de Parkinson 4Estados Unidos
-
National Heart, Lung, and Blood Institute (NHLBI)TerminadoEnfermedad de Parkinson 6, inicio temprano | Enfermedad de Parkinson (autosómica recesiva, aparición temprana) 7, humana | Enfermedad de Parkinson Autosómica Recesiva, Inicio Temprano | Enfermedad de Parkinson, autosómica recesiva de aparición temprana, digénica, Pink1/Dj1Estados Unidos
-
Assiut UniversityAún no reclutandoMri en Parkinson
-
Medical College of WisconsinRetirado
-
Hacettepe UniversityTerminadoEnfermedad de Parkinson idiopáticaPavo
-
Pôle Saint HélierRennes University Hospital; Réseau Parkinson BretagneTerminadoEnfermedad de Parkinson | Síndrome de ParkinsonFrancia
-
UCB PharmaTerminadoEnfermedad de Parkinson idiopáticaAlemania
-
King's College LondonGlaxoSmithKlineTerminadoEnfermedad de Parkinson | Enfermedad de Parkinson idiopática | Enfermedad de Parkinson, PARK8Reino Unido
-
UCB PharmaTerminadoENFERMEDAD DE PARKINSON IDIOPÁTICAPorcelana
-
AbbVie (prior sponsor, Abbott)Quintiles, Inc.TerminadoEnfermedad de Parkinson avanzadaEstados Unidos, Nueva Zelanda
Ensayos clínicos sobre DBS
-
Chinese PLA General HospitalAún no reclutandoDistonía cervicalPorcelana
-
University Medical Center GroningenDesconocido
-
Deep Brain Innovations LLCTerminadoEnfermedad de ParkinsonEstados Unidos
-
University of Southern CaliforniaTerminadoEnfermedad de ParkinsonEstados Unidos
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Radboud University Medical Center; University Medical Center Groningen; Maastricht... y otros colaboradoresReclutamientoEnfermedades del Sistema Nervioso Central | Temblor esencial | Estimulación cerebral profunda | Resonancia magnetica | Imágenes de tensor de difusiónPaíses Bajos
-
Ruijin HospitalNational Natural Science Foundation of China; Icahn School of Medicine at Mount... y otros colaboradoresRetiradoTrastorno obsesivo compulsivoPorcelana
-
University of British ColumbiaAún no reclutandoDisfonía espasmódicaCanadá
-
Functional Neuromodulation LtdActivo, no reclutandoEnfermedad de AlzheimerEstados Unidos, Canadá, Alemania
-
Stanford UniversityReclutamientoEnfermedad de ParkinsonEstados Unidos
-
St. Joseph's Hospital and Medical Center, PhoenixTerminadoEnfermedad de Parkinson | Demencia | Defecto cognitivo leveEstados Unidos